An interventional study of Very Low Nicotine Cigarettes (VLNC) and Normal Nicotine Cigarettes (NNC) in Chronic Pain, Tobacco Use and Opioid Substitution Treatment, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by Duke University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Chronic Pain by Duke University — 5 open to participants now, 5 under way, none of them phase 3. Chronic Pain · Duke University.
Among the 19 studies in Chronic Pain by Duke University, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 16th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →5 of the 19 studies in Chronic Pain by Duke University are open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 21–65
Duke University · Sites in United States
Ages 15–40
Duke University · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 99 across the 16 interventional studies, 81 across the 3 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
3 of the studies in Chronic Pain by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07525063Duke UniversityPain & Reward Neuromodulation of CNS Circuits | 2026-12 |
| NCT05905419Duke UniversityNeuroimaging of Opioid Phase (OPAL) | 2027-06-30 |
| NCT06747871Duke UniversityOpioids, Low Nicotine Cigarettes, and Chronic Pain | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Chronic Pain by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of switching to very low nicotine content (VLNC) cigarettes versus normal nicotine content (NNC) cigarettes on craving, withdrawal, and pain among individuals with chronic pain who smoke cigarettes daily and are attending office-based buprenorphine treatment (OBBT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this condition will be provided with VLNCs and asked to switch to smoking only study cigarettes for 4 weeks.
Behavioral: Very Low Nicotine Cigarettes (VLNC)
Participants in this condition will be provided with NNCs and asked to switch to smoking only study cigarettes for 4 weeks.
Behavioral: Normal Nicotine Cigarettes (NNC)
Spectrum NRC 102/103 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco.
Spectrum NRC 600/601 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco.
Nicotine Dependence as measured by the Fagerstrom Test of Cigarette Dependence (FTCD)
The FTCD has a total score of 0 to 10, where a greater score indicates a greater physical dependence on nicotine.
Time frame: Baseline and weekly during study cigarette use (4 weeks)
Cigarettes per Day
Average cigarettes smoked per day during the past week will be calculated using timeline follow-back methods
Time frame: Baseline and weekly during study cigarette use (4 weeks)
Pain as measured by the Brief Pain Inventory (BPI)
The BPI has an averaged score of 0 to 10, where a greater score indicates greater pain.
Time frame: Baseline, during abstinence sessions, and at weekly visits during study cigarette use (4 weeks)
Mechanical Hyperalgesia
Mechanical hyperalgesia is a condition that causes increased sensitivity to mechanical stimuli after an injury to the skin. Discriminability and response bias will be assessed using a computerized pressure algometer.
Time frame: Weekly visits 1 and 5 during study cigarette use (4 weeks), and during abstinence sessions
Smoking Withdrawal as measured by the Minnesota Withdrawal Scale (MNWS)
The MNWS has a total score range of 0 to 68, where a higher score indicates greater symptoms of withdrawal.
Time frame: Baseline, during abstinence sessions, and at weekly visits during study cigarette use (4 weeks)
Cigarette Craving as measured by the Questionnaire of Smoking Urges-Brief (QSU-B)
The QSU-B has a total score range of 0 to 100, where a higher score indicates greater craving.
Time frame: Baseline, during abstinence sessions, and at weekly visits during study cigarette use (4 weeks)
Cigarette Purchase Task - demand intensity
Outcomes for the cigarette purchase task will include demand intensity (i.e., consumption at $0) and Omax (i.e., max expenditure at any price point).
Time frame: Weekly visits 1 and 5 during study cigarette use (4 weeks), and during abstinence sessions
Cigarette Purchase Task - Omax
Outcomes for the cigarette purchase task will include demand intensity (i.e., consumption at $0) and Omax (i.e., max expenditure at any price point).
Time frame: Weekly visits 1 and 5 during study cigarette use (4 weeks), and during abstinence sessions
Pain-Smoking Associations as measured by Ecological Momentary Assessment (EMA)
EMA (also called experience sampling or daily diary method) involves repeated sampling of people's current experiences (e.g. pain) in real time in their natural environments.
Time frame: Baseline, weeks 1 and 4 of study cigarette use
Buprenorphine-smoking associations as measured by Ecological Momentary Assessment (EMA) - smoking frequency
Within-person variability in smoking frequency assessed via EMA before and after buprenorphine administration.
Time frame: Baseline, weeks 1 and 4 of study cigarette use
Buprenorphine-smoking associations as measured by Ecological Momentary Assessment (EMA) - craving
Within-person variability in smoking craving assessed via EMA before and after buprenorphine administration.
Time frame: Baseline, weeks 1 and 4 of study cigarette use
Opioid Withdrawal as measured by the Short Opioid Withdrawal Scale (SOWS)
The SOWS consists of 16 symptoms rated in intensity by patients on a 5-point scale of intensity as follows: 0-not at all, 1-a little, 2-moderately, 3-quite a bit, 4-extremely. The total score ranges from 0 to 64, where a higher score indicates greater symptoms of withdrawal.
Time frame: Baseline, during abstinence sessions, and at weekly visits during study cigarette use (4 weeks)
Number of participants willing to Quit Smoking
Decision (yes/no) to engage in the optional quit attempt
Time frame: post-intervention, after 24 hrs abstinence
Smoking abstinence self-efficacy as measured by the Self-Efficacy Questionnaire (SEQ)
The SEQ has a total score range of 10 to 40, where a higher score indicates greater self-efficacy.
Time frame: Weekly visits 1 and 5
Pain and Smoking Inventory (PSI)
The PSI total score is computed by averaging scores across the nine items. Items are endorsed on a seven-point Likert scale anchored at 0 (not true at all), 3 (somewhat true), and 6 (extremely true). Scores range from 0 to 6, where higher scores indicate greater perceptions that pain and smoking are interrelated.
Time frame: Weekly visits 1 and 5
Barriers to Quitting Smoking in Substance Abuse Treatment (BSQ-SAT)
The BQS-SAT is an 11-item true-false instrument of perceived barriers to quitting smoking plus one open-ended item. The score can range from 0 to 4.86, where a higher score indicates a greater perceived barrier.
Time frame: Weekly visits 1 and 5
Plan to share: Yes — The final dataset will include demographic, interview and self-report data. The investigators will share de-identified individual-participant level (IPD) data. Appropriate measures will be used for data de-identification and sharing, and informed consent will reflect those plans.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jul 2027, 27 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 27 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.